In This Section

Program

Monday, October 19, 2020

Tuesday, October 20, 2020

MONDAY, OCTOBER 19, 2020

OPENING REMARKS AND KEYNOTES
10-11:20 A.M.

Clinical development of BCMA-directed therapies in multiple myeloma
Kristen M. Hege, Celgene Corporation, San Francisco, California

A case for priming, not checkpoint
Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

Break
11:20-11:35 A.M.
Plenary Session 1: Synthetic Biology and Novel Approaches to Immune Engineering
11:35 A.M.-1:20 A.M.

Engineering artificial Antigen Presenting Complexes, aAPC, for cancer immunotherapy: From bench to bedside
Jonathan P. Schneck, Johns Hopkins University School of Medicine, Baltimore, Maryland

Additional speakers to be announced

Short talks from selected abstracts

Break
1:20-1:35 P.M.
Plenary Session 2: Innate and Adaptive Checkpoints
1:35 P.M.-3:35 P.M.      

Targeting macrophages to promote anti-tumor immunity
Judith A. Varner, UCSD Moores Cancer Center, San Diego, California

Innate immune defenses against cancer: Potential for mobilizing NK cells for cancer immunotherapy
David H. Raulet, University of California, Berkeley, Berkeley, California

Additional speaker to be announced

Short talks from selected abstracts

Break
3:20-3:35 P.M.
Plenary Session 3: Novel Combinations
3:35-5:20 P.M.

Title to be announced
Charles G. Drake, Columbia University Irving Medical Center, New York, New York

The QuEST for an effective immunotherapy for prostate cancer
James L. Gulley, National Cancer Institute, Bethesda, Maryland

What are some different ways to evaluate immunotherapy combinations?
Michael Postow, Memorial Sloan Kettering Cancer Center, New York, New York

TUESDAY, OCTOBER 20, 2020

Day 2 Keynote Presentation
10-10:40 A.M.

Title to be announced
Laurie H. Glimcher, Dana-Farber Cancer Institute, Boston, Massachusetts

Break
10:40-10:55 A.M.
Plenary Session 4: Vaccines, Neoantigens, and Oncolytic Viruses
10:55-11:25 A.M.

Building improved personal cancer vaccines
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Adrian Hill, Jenner Institute at Oxford University, Oxford, England

Short talks from selected abstracts

Break
12:25-12:40 P.M.
Plenary Session 5: Non-T-Cell Therapies
12:40-2:10 P.M.

Title to be announced
Adrian C. Hayday, The Francis Crick Institute, London, England

The Future of CAR Therapies
Elizabeth J. Shpall, MD Anderson Cancer Center, Houston, Texas

Short talks from selected abstracts

Break
2:10-2:25 P.M.
Plenary Session 6: T-Cell Therapies
2:25-3:55 P.M.

Title to be announced
Avery D. Posey, University of Pennsylvania, Philadelphia, Pennsylvania

Title to be announced
Renier J. Brentjens, Memorial Sloan Kettering Cancer Institute, New York, New York

Short talks from selected abstracts

Break
3:55-4:10 P.M.
Plenary Session 7: Defining Novel Immunotherapy Targets
4:10-5:40 P.M.

Title to be announced
Arlene H. Sharpe, Harvard Medical School, Boston, Massachusetts

Probing the immune system in cancer
Stephen J. Elledge, Harvard Medical School, Boston, Massachusetts

Short talks from selected abstracts

Closing remarks
5:40